[1]
Leitão Guerra RL, Leitão Guerra CL, Bastos MG, de Oliveira AHP, Salles C. Sickle cell retinopathy: What we now understand using optical coherence tomography angiography. A systematic review. Blood reviews. 2019 May:35():32-42. doi: 10.1016/j.blre.2019.03.001. Epub 2019 Mar 4
[PubMed PMID: 30852057]
Level 1 (high-level) evidence
[2]
Walkden A, Griffin B, Cheng C, Dhawahir-Scala F. Gross anterior segment ischaemia following vitreoretinal surgery for sickle-cell retinopathy. BMJ case reports. 2019 Jan 29:12(1):. doi: 10.1136/bcr-2018-227541. Epub 2019 Jan 29
[PubMed PMID: 30700461]
Level 3 (low-level) evidence
[3]
Stultz RD, Conti FF, Kumar JB, Kotabish E, Schachat A, Ehlers JP, Saunthararajah Y, Singh RP. Beta-Thalassemia Minor Manifesting as Proliferative Retinopathy. Ophthalmic surgery, lasers & imaging retina. 2018 Oct 1:49(10):e161-e164. doi: 10.3928/23258160-20181002-22. Epub
[PubMed PMID: 30395680]
[4]
Lim WS, Magan T, Mahroo OA, Hysi PG, Helou J, Mohamed MD. Retinal thickness measurements in sickle cell patients with HbSS and HbSC genotype. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie. 2018 Aug:53(4):420-424. doi: 10.1016/j.jcjo.2017.10.006. Epub 2017 Dec 11
[PubMed PMID: 30119799]
[5]
Skinner SC, Diaw M, Pialoux V, Mbaye MN, Mury P, Lopez P, Bousquet D, Gueye F, Diedhiou D, Joly P, Renoux C, Sow D, Diop S, Ranque B, Vinet A, Samb A, Guillot N, Connes P. Increased Prevalence of Type 2 Diabetes-Related Complications in Combined Type 2 Diabetes and Sickle Cell Trait. Diabetes care. 2018 Dec:41(12):2595-2602. doi: 10.2337/dc18-1289. Epub 2018 Oct 16
[PubMed PMID: 30327363]
[6]
Ribeiro MVMR, Jucá JVO, Alves ALCDS, Ferreira CVO, Barbosa FT, Ribeiro ÊAN. Sickle cell retinopathy: A literature review. Revista da Associacao Medica Brasileira (1992). 2017 Dec:63(12):1100-1103. doi: 10.1590/1806-9282.63.12.1100. Epub
[PubMed PMID: 29489976]
[7]
Do BK, Rodger DC. Sickle cell disease and the eye. Current opinion in ophthalmology. 2017 Nov:28(6):623-628. doi: 10.1097/ICU.0000000000000423. Epub
[PubMed PMID: 28984727]
Level 3 (low-level) evidence
[8]
Bilong Y, Dubert M, Koki G, Noubiap JJ, Pangetna HN, Menet A, Chelo D, Offredo L, Jacob S, Belinga S, Yanda ANA, Kingue S, Jouven X, Ranque B, Bella LA. Sickle cell retinopathy and other chronic complications of sickle cell anemia: A clinical study of 84 Sub-Saharan African cases (Cameroon). Journal francais d'ophtalmologie. 2018 Jan:41(1):50-56. doi: 10.1016/j.jfo.2017.07.005. Epub 2017 Dec 30
[PubMed PMID: 29295792]
Level 3 (low-level) evidence
[9]
Elagouz M, Jyothi S, Gupta B, Sivaprasad S. Sickle cell disease and the eye: old and new concepts. Survey of ophthalmology. 2010 Jul-Aug:55(4):359-77. doi: 10.1016/j.survophthal.2009.11.004. Epub 2010 May 10
[PubMed PMID: 20452638]
Level 3 (low-level) evidence
[10]
Scott AW. Ophthalmic Manifestations of Sickle Cell Disease. Southern medical journal. 2016 Sep:109(9):542-8. doi: 10.14423/SMJ.0000000000000525. Epub
[PubMed PMID: 27598358]
[11]
Liaska A, Petrou P, Georgakopoulos CD, Diamanti R, Papaconstantinou D, Kanakis MG, Georgalas I. β-Thalassemia and ocular implications: a systematic review. BMC ophthalmology. 2016 Jul 8:16():102. doi: 10.1186/s12886-016-0285-2. Epub 2016 Jul 8
[PubMed PMID: 27390837]
Level 1 (high-level) evidence
[12]
Bhoiwala DL, Dunaief JL. Retinal abnormalities in β-thalassemia major. Survey of ophthalmology. 2016 Jan-Feb:61(1):33-50. doi: 10.1016/j.survophthal.2015.08.005. Epub 2015 Aug 29
[PubMed PMID: 26325202]
Level 3 (low-level) evidence
[13]
Amissah-Arthur KN, Mensah E. The past, present and future management of sickle cell retinopathy within an African context. Eye (London, England). 2018 Aug:32(8):1304-1314. doi: 10.1038/s41433-018-0162-8. Epub 2018 Jul 10
[PubMed PMID: 29991740]
[14]
Boshuizen M, van der Ploeg K, von Bonsdorff L, Biemond BJ, Zeerleder SS, van Bruggen R, Juffermans NP. Therapeutic use of transferrin to modulate anemia and conditions of iron toxicity. Blood reviews. 2017 Nov:31(6):400-405. doi: 10.1016/j.blre.2017.07.005. Epub 2017 Jul 24
[PubMed PMID: 28755795]